FLAG方案治疗复发或难治性急性髓系白血病临床观察

目的:探讨FLAG方案治疗复发或难治性急性髓系白血病患者的疗效。方法:采用FLAG方案治疗复发或难治性急性髓系白血病患者37例。FLAG方案为氟达拉滨(Flu)30 mg/m2,dl～d5,阿糖胞苷(Ara-C)2 g,d1～d5,粒细胞集落刺激因子(G-CSF)5μg/kg d0直到白细胞恢复超过>1.5×109/L。结果:37例患者中12例完全缓解(CR),CR率为32.4%。随访中位总生存期(overall survival,OS)为6.2个月,中位无进展生存期(progression-freesurvival,PFS)为10.3个月。26例复发患者FLAG方案治疗前少于3个疗程化疗的患者与3个及3个以上化疗疗程的患者疗效比较,差异有统计学意义(P<0.01)。结论:FLAG方案治疗复发、难治的急性髓系白血病患者效果良好。

Effect of FLAG program on relapsed or refractory acute myeloid leukemia cases

Objective： To study the effect of FLAG program on relapsed or refractory acute myeloid leukemia.Methods：A total of 37 patients with relapsed or refractory acute myeloid leukemia were treated with FLAG program： fludarabine 30 mg/m2,dl-d5,Ara-C 2 g,d1-d5,granulocyte colony stimulating factor（G-CSF） 5 μg/kg d0 until the white blood cell recovery above 1.5 × 109 / L.Results： 12 cases had complete remission（CR）,CR rate was 32.4%.The median overall survival（OS） was 6.2 months,median progress free survival（PFS） was 10.3 months.There was significant difference between recurrence patients with pre-FLAG treatment of less than 3 cycles of chemotherapy and patients with three or more cycles of chemotherapy（P0.01） in 26 cases.Conclusions： FLAG program is a better choice for relapse or refractory patients with acute myelogenous leukemia.